Shopping Cart 0
Cart Subtotal
USD 0

Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (ATM) and super-benzopyrans (SBP). ATM drugs that target the cancer cell cytoskeleton are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. SBP drugs that target cancer stem cells are being developed for the treatment of ovarian cancer and glioblastoma. The PI3K inhibitor functions by inhibiting an important signaling pathway which is critical to the development of certain kinds of tumors. The company's product pipeline includes PI3K GDC-0084; Cantrixil (TRX-E-002-1). Kazia is headquartered in New South Wales, Australia.

Kazia Therapeutics Ltd (KZA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Novogen Acquires Anti-Tropomyosins Drug Technology From Genscreen 12

Partnerships 14

Kazia Therapeutics Enters into Partnership with Dana-Farber Cancer Institute 14

Kazia Therapeutics Enters into Co-Development Agreement with St Jude Children's Research Hospital 15

Noxopharm Enters into Agreement with Kazia Therapeutics 16

Novogen Enters into Contract Research Agreement with Novotech 17

Novogen to Enter into Co-Development Agreement with Feinstein Institute for Medical Research for Brain Cancer 18

Novogen Enters into Agreement with Genea Biocells 19

Novogen Forms Joint Venture With Yale University 20

Novogen Enters Into Agreement With The Ingham Institute For Applied Medical Research 22

Licensing Agreements 23

Heaton-Brown Life Sciences Enters into Licensing Agreement with Novogen 23

Novogen Enters into Licensing Agreement with Genentech for GDC-0084 24

Equity Offering 25

Kazia Therapeutics Raises USD0.6 Million in Share Purchase Plan 25

Kazia Therapeutics Raises USD2.4 Million in Private Placement of Shares 26

Kazia Therapeutics Files Registration Statement for Public Offering of American Depositary Shares and Warrants for up to USD100 Million 28

Novogen Raises USD13 Million in Rights Offering of Shares 29

Novogen to Raise USD0.51 Million in Private Placement of Shares 31

Novogen Raises USD12 Million in Private Placement of Shares 32

Novogen to Raise Additional USD1.4 million in Private Placement of Shares 33

Novogen Raises USD1.6 Million in Private Placement of Shares 35

Novogen Completes Second Tranche Of Private Placement Of Shares For USD 0.14 Million 36

Novogen Completes Rights Offering Of Shares For USD 0.8 Million 37

Novogen Completes Private Placement Of Shares For USD 2 Million 38

Debt Offering 39

Novogen Completes Third Tranche of Private Placement Of Private Placement Of Note For USD 3.7 Million 39

Asset Transactions 40

TroBio Therapeutics Acquires ATM Program from Kazia Therapeutics 40

TR Therapeutics Completes Acquisition Of Glucan Technology Assets From Novogen 41

Acquisition 42

Novogen Acquires Glioblast for USD1.6 Million 42

Novogen Completes Acquisition Of Triaxial Pharma For USD 2 Million 43

Kazia Therapeutics Ltd-Key Competitors 44

Kazia Therapeutics Ltd-Key Employees 45

Kazia Therapeutics Ltd-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Financial Announcements 47

Aug 29, 2017: Novogen Annual Report And Full-year Financial Results 47

Corporate Communications 49

Jun 08, 2017: Novogen Streamlines Board and Costs 49

Mar 10, 2017: Novogen Announces Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure 50

Mar 10, 2017: Novogen: Transformation To A Clinical Stage Organisation Leads To Changes In Management Structure 51

Product News 52

05/07/2018: Emerging oncology researcher says women lose out as ovarian cancer treatments lag 52

Clinical Trials 53

Sep 13, 2018: Australian clinical trial of ovarian cancer therapy Cantrixil pivotal for cancer stem cell research 53

Jun 19, 2018: Kazia Releases Preliminary Cantrixil Phase I Data 54

Aug 07, 2017: Progress Update on Cantrixil (TRXE-002-1) Development 55

Other Significant Developments 57

Feb 19, 2018: Kazia Change Of Registered Office And Business Address 57

Aug 14, 2017: Novogen: Board Review Of Business Operations And Governance 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kazia Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novogen Acquires Anti-Tropomyosins Drug Technology From Genscreen 12

Kazia Therapeutics Enters into Partnership with Dana-Farber Cancer Institute 14

Kazia Therapeutics Enters into Co-Development Agreement with St Jude Children's Research Hospital 15

Noxopharm Enters into Agreement with Kazia Therapeutics 16

Novogen Enters into Contract Research Agreement with Novotech 17

Novogen to Enter into Co-Development Agreement with Feinstein Institute for Medical Research for Brain Cancer 18

Novogen Enters into Agreement with Genea Biocells 19

Novogen Forms Joint Venture With Yale University 20

Novogen Enters Into Agreement With The Ingham Institute For Applied Medical Research 22

Heaton-Brown Life Sciences Enters into Licensing Agreement with Novogen 23

Novogen Enters into Licensing Agreement with Genentech for GDC-0084 24

Kazia Therapeutics Raises USD0.6 Million in Share Purchase Plan 25

Kazia Therapeutics Raises USD2.4 Million in Private Placement of Shares 26

Kazia Therapeutics Files Registration Statement for Public Offering of American Depositary Shares and Warrants for up to USD100 Million 28

Novogen Raises USD13 Million in Rights Offering of Shares 29

Novogen to Raise USD0.51 Million in Private Placement of Shares 31

Novogen Raises USD12 Million in Private Placement of Shares 32

Novogen to Raise Additional USD1.4 million in Private Placement of Shares 33

Novogen Raises USD1.6 Million in Private Placement of Shares 35

Novogen Completes Second Tranche Of Private Placement Of Shares For USD 0.14 Million 36

Novogen Completes Rights Offering Of Shares For USD 0.8 Million 37

Novogen Completes Private Placement Of Shares For USD 2 Million 38

Novogen Completes Third Tranche of Private Placement Of Private Placement Of Note For USD 3.7 Million 39

TroBio Therapeutics Acquires ATM Program from Kazia Therapeutics 40

TR Therapeutics Completes Acquisition Of Glucan Technology Assets From Novogen 41

Novogen Acquires Glioblast for USD1.6 Million 42

Novogen Completes Acquisition Of Triaxial Pharma For USD 2 Million 43

Kazia Therapeutics Ltd, Key Competitors 44

Kazia Therapeutics Ltd, Key Employees 45

Kazia Therapeutics Ltd, Subsidiaries 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Kazia Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (ATM) and super-benzopyrans (SBP). ATM drugs that target the cancer cell cytoskeleton are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. SBP drugs that target cancer stem cells are being developed for the treatment of ovarian cancer and glioblastoma. The PI3K inhibitor functions by inhibiting an important signaling pathway which is critical to the development of certain kinds of tumors. The company's product pipeline includes PI3K GDC-0084; Cantrixil (TRX-E-002-1). Kazia is headquartered in New South Wales, Australia.

Kazia Therapeutics Ltd (KZA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Novogen Acquires Anti-Tropomyosins Drug Technology From Genscreen 12

Partnerships 14

Kazia Therapeutics Enters into Partnership with Dana-Farber Cancer Institute 14

Kazia Therapeutics Enters into Co-Development Agreement with St Jude Children's Research Hospital 15

Noxopharm Enters into Agreement with Kazia Therapeutics 16

Novogen Enters into Contract Research Agreement with Novotech 17

Novogen to Enter into Co-Development Agreement with Feinstein Institute for Medical Research for Brain Cancer 18

Novogen Enters into Agreement with Genea Biocells 19

Novogen Forms Joint Venture With Yale University 20

Novogen Enters Into Agreement With The Ingham Institute For Applied Medical Research 22

Licensing Agreements 23

Heaton-Brown Life Sciences Enters into Licensing Agreement with Novogen 23

Novogen Enters into Licensing Agreement with Genentech for GDC-0084 24

Equity Offering 25

Kazia Therapeutics Raises USD0.6 Million in Share Purchase Plan 25

Kazia Therapeutics Raises USD2.4 Million in Private Placement of Shares 26

Kazia Therapeutics Files Registration Statement for Public Offering of American Depositary Shares and Warrants for up to USD100 Million 28

Novogen Raises USD13 Million in Rights Offering of Shares 29

Novogen to Raise USD0.51 Million in Private Placement of Shares 31

Novogen Raises USD12 Million in Private Placement of Shares 32

Novogen to Raise Additional USD1.4 million in Private Placement of Shares 33

Novogen Raises USD1.6 Million in Private Placement of Shares 35

Novogen Completes Second Tranche Of Private Placement Of Shares For USD 0.14 Million 36

Novogen Completes Rights Offering Of Shares For USD 0.8 Million 37

Novogen Completes Private Placement Of Shares For USD 2 Million 38

Debt Offering 39

Novogen Completes Third Tranche of Private Placement Of Private Placement Of Note For USD 3.7 Million 39

Asset Transactions 40

TroBio Therapeutics Acquires ATM Program from Kazia Therapeutics 40

TR Therapeutics Completes Acquisition Of Glucan Technology Assets From Novogen 41

Acquisition 42

Novogen Acquires Glioblast for USD1.6 Million 42

Novogen Completes Acquisition Of Triaxial Pharma For USD 2 Million 43

Kazia Therapeutics Ltd-Key Competitors 44

Kazia Therapeutics Ltd-Key Employees 45

Kazia Therapeutics Ltd-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Financial Announcements 47

Aug 29, 2017: Novogen Annual Report And Full-year Financial Results 47

Corporate Communications 49

Jun 08, 2017: Novogen Streamlines Board and Costs 49

Mar 10, 2017: Novogen Announces Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure 50

Mar 10, 2017: Novogen: Transformation To A Clinical Stage Organisation Leads To Changes In Management Structure 51

Product News 52

05/07/2018: Emerging oncology researcher says women lose out as ovarian cancer treatments lag 52

Clinical Trials 53

Sep 13, 2018: Australian clinical trial of ovarian cancer therapy Cantrixil pivotal for cancer stem cell research 53

Jun 19, 2018: Kazia Releases Preliminary Cantrixil Phase I Data 54

Aug 07, 2017: Progress Update on Cantrixil (TRXE-002-1) Development 55

Other Significant Developments 57

Feb 19, 2018: Kazia Change Of Registered Office And Business Address 57

Aug 14, 2017: Novogen: Board Review Of Business Operations And Governance 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kazia Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novogen Acquires Anti-Tropomyosins Drug Technology From Genscreen 12

Kazia Therapeutics Enters into Partnership with Dana-Farber Cancer Institute 14

Kazia Therapeutics Enters into Co-Development Agreement with St Jude Children's Research Hospital 15

Noxopharm Enters into Agreement with Kazia Therapeutics 16

Novogen Enters into Contract Research Agreement with Novotech 17

Novogen to Enter into Co-Development Agreement with Feinstein Institute for Medical Research for Brain Cancer 18

Novogen Enters into Agreement with Genea Biocells 19

Novogen Forms Joint Venture With Yale University 20

Novogen Enters Into Agreement With The Ingham Institute For Applied Medical Research 22

Heaton-Brown Life Sciences Enters into Licensing Agreement with Novogen 23

Novogen Enters into Licensing Agreement with Genentech for GDC-0084 24

Kazia Therapeutics Raises USD0.6 Million in Share Purchase Plan 25

Kazia Therapeutics Raises USD2.4 Million in Private Placement of Shares 26

Kazia Therapeutics Files Registration Statement for Public Offering of American Depositary Shares and Warrants for up to USD100 Million 28

Novogen Raises USD13 Million in Rights Offering of Shares 29

Novogen to Raise USD0.51 Million in Private Placement of Shares 31

Novogen Raises USD12 Million in Private Placement of Shares 32

Novogen to Raise Additional USD1.4 million in Private Placement of Shares 33

Novogen Raises USD1.6 Million in Private Placement of Shares 35

Novogen Completes Second Tranche Of Private Placement Of Shares For USD 0.14 Million 36

Novogen Completes Rights Offering Of Shares For USD 0.8 Million 37

Novogen Completes Private Placement Of Shares For USD 2 Million 38

Novogen Completes Third Tranche of Private Placement Of Private Placement Of Note For USD 3.7 Million 39

TroBio Therapeutics Acquires ATM Program from Kazia Therapeutics 40

TR Therapeutics Completes Acquisition Of Glucan Technology Assets From Novogen 41

Novogen Acquires Glioblast for USD1.6 Million 42

Novogen Completes Acquisition Of Triaxial Pharma For USD 2 Million 43

Kazia Therapeutics Ltd, Key Competitors 44

Kazia Therapeutics Ltd, Key Employees 45

Kazia Therapeutics Ltd, Subsidiaries 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Kazia Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.